ArticleCureus2025
Factors Associated With Complications in Patients With Hematological Malignancies and Febrile Neutropenia: A Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Febrile neutropenia (FN) in patients with hematological malignancy (HM) is associated with multiple hospital complications including mortality. Although different strategies for early detection and prompt treatment have been established, it is a heterogeneous population with risk factors that are difficult to detect. The data available on the prediction of such complications is limited and there lies the importance of characterizing this type of patients in our environment and evaluating the factors related to the adverse outcomes. Methods The study is a retrospective cohort study conducted at San Vicente Foundation University Hospital (HUSVF) and Alma Mater Hospital of Antioquia (HAMA) in Medellín, Colombia, between January 2018 and December 2020, including patients diagnosed with FN who presented FN at the time of diagnosis or up to 30 days after receiving chemotherapy. The main objective was to determine the factors related to mortality and severe complications (ICU admission, need for vasopressors, or need for mechanical ventilation), while the secondary objective was the microbiological characterization of this population. Results Of the 190 FN episodes, 134 (70.5%) had a clinical focus of infection. A causal agent was identified in 125 episodes (65.8%), with the majority being bacteria in 112 cases (92.6%) of the isolates. The most frequently identified bacteria were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.